Atrial Myxomas Grow Faster Than We Think

Walpot, Jeroen; Shivalkar, F.E.S.C. Bharati; Rodrigus, Inez; Pasteuning, W. Hans; Hokken, Raymond B.

doi:10.1111/j.1540-8175.2010.01186.x

Cited by 27 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myxomas vary in size, but the growth rate is difficult to document because they are usually removed after diagnosis [6–9]. However, in our study, the one patient who underwent surgery 15 months after initial diagnosis showed a rapid growth rate of 0.41 cm/month.…”

Section: Discussionmentioning

confidence: 65%

Surgical resection of cardiac myxoma—a 30-year single institutional experience

Lee

Kim

Jung

et al. 2017

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundPrimary cardiac tumors are rare and myxoma constitutes the majority. The present study summarizes our 30-year clinical outcomes of surgical myxoma resection.MethodsBetween January 1986 and December 2015, 93 patients (30 men, 63 women; mean age, 54.7 ± 16.6 years) underwent surgical myxoma resection. The most common origin site was the left atrium. Surgery was performed via a biatrial approach in 74.2%, atrial septotomy through right atriotomy in 17.2%, and left atriotomy only in 8.6%. Mean myxoma size based on longest length was 4.73 ± 1.92 cm (range, 1.2–11.0 cm).ResultsThe mean follow-up duration was 9.9 ± 7.8 years (range, 0–29 years). In-hospital mortality was 3.2%. The most common postoperative complication was atrial fibrillation (4.3%). The 5-, 10-, and 30-year survival rates were 92.9%, 87.2%, and 75.5%, respectively. Recurrence occurred in two patients (2.1%), which were detected at 20 and 79 months after the first surgery, respectively.ConclusionsLong-term survival after myxoma resection was excellent and recurrence was rare. Based on our experience, surgical method did not affect the outcome.

show abstract

Section: Discussionmentioning

confidence: 65%

Surgical resection of cardiac myxoma—a 30-year single institutional experience

Lee

Kim

Jung

et al. 2017

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…As many as 4% of patients remain asymptomatic [4]. Atrial myxomas may grow quite rapidly, with a reported growth rates of average 0.49 cm/month [5]. Our patient had no detectable mass by CT only eight months earlier.…”

Section: Discussionmentioning

confidence: 59%

Acute Respiratory Distress after Knee Arthroplasty Due to Undiagnosed Atrial Myxoma

Khan¹,

Yang²,

Mallidi³

et al. 2012

OJAnes

View full text Add to dashboard Cite

Acute postoperative respiratory distress may be caused by pneumonia, pulmonary embolism, heart failure, pneumothorax or atelectasis. We present s case report of a 78-year-old female patient who developed acute respiratory distress one day following knee arthroscopy. Because of the suspicion of pulmonary embolism, a computed tomographic angiography was made, showing the presence of an unexpected large left atrial mass, suggestive for a myxoma. She underwent successful resection of a 10 × 5 cm myxoma one week later. The report discusses the clinical manifestations of an atrial myxoma and its potentially fast growth. Bedside echocardiography should be considered the preferred diagnostic modality in case of acute postoperative respiratory distress.

show abstract

“…Our immunohistology data confirmed the expression of CD44 in myxoma. As a widely used cancer stem cell marker, CD44 expression indicates the malignant potential of cardiac myxoma [12]. It has been reported that myxomas are mainly composed of cellular elements including a variable number of blood cells [2] and amorphous myxoid matrix structures [13].…”

Section: Resultsmentioning

confidence: 99%

Identification of Stem‐Like Cells in Atrial Myxoma by Markers CD44, CD19, and CD45

Song

Liu

Cui

et al. 2016

Stem Cells International

View full text Add to dashboard Cite

Atrial myxoma is the most frequent tumor arising mainly in atrial septum and its origin remains uncertain. It has been reported that a subpopulation of stem-like cells are present in benign tumors and responsible for tumor initiation and maintenance. In this study, we investigated whether stem-like cells could contribute to the atrial cardiac myxoma. Immunohistology data confirmed that a population of cells bearing the surface markers CD19, CD45, and CD44 resided in a mucopolysaccharide-rich matrix of myxoma. Moreover, we isolated myxoma cells with phase-bright culture method and confirmed that myxoma derived cells express robust level of CD19, CD45, and CD44. Furthermore, the pluripotency of this population of cells also was validated by cardiomyocytes and smooth muscle cells differentiation in vitro. Our results indicate that primary cardiac myxoma may arise from mesenchymal stem cells with the ability to generate tumors with multilineage differentiation. In conclusion, this study for the first time verified that stem-like cells are present in atrial myxoma and this population of cells may have the capacity for myxoma initiation and progression.

show abstract

Atrial Myxomas Grow Faster Than We Think

Cited by 27 publications

References 22 publications

Surgical resection of cardiac myxoma—a 30-year single institutional experience

Surgical resection of cardiac myxoma—a 30-year single institutional experience

Acute Respiratory Distress after Knee Arthroplasty Due to Undiagnosed Atrial Myxoma

Identification of Stem‐Like Cells in Atrial Myxoma by Markers CD44, CD19, and CD45

Contact Info

Product

Resources

About